Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SASnegha AnanthJMJayasindhu MallampetKKKatherine A. Kong

Discussion

Loading...

Member takes

Overview

Observational study reveals ctDNA enhances surveillance in large B-cell lymphoma, suggesting reduced PET-CT reliance.

Key Points

  • Evaluate ctDNA-based monitoring following CD19 CAR T-cell therapy, focusing on its prognostic ability in large B-cell lymphoma.
  • Prospective, observational study of patients receiving CD19 CAR T-cell therapy.
  • Pre-planned plasma collection at several time points to track measurable residual disease using ctDNA.
  • PET-CT performed pre-therapy and at multiple follow-ups for disease response assessment.
  • 142 patients analyzed with a median follow-up of 17.2 months for axi-cel and 11.5 months for liso-cel.
  • ctDNA levels predicted progression-free survival, especially significant at Day 14 for axi-cel.
  • Detection of ctDNA often appeared before clinical relapse, with a high negative predictive value for undetectable ctDNA.

Cite This Study

Ananth et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcadhttps://doi.org/10.1182/blood-2025-941
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy2024 · 21 citations
  2. 2Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas2025 · 2 citations
  3. 3Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study2025
  4. 4Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas2025
  5. 5Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL.2026